Boston Scientific Corporation filings document the regulatory record of a global medical technology company with device and therapy portfolios for cardiovascular, respiratory, digestive, oncological, neurological and urological conditions. Recent 8-K reports furnish operating results, clinical-trial announcements and other material events tied to products such as WATCHMAN and EKOS.
Proxy and governance filings cover director elections, executive compensation, stockholder votes, board committee matters and amendments to the company’s certificate of incorporation. Additional disclosures address capital resources and financing arrangements, including revolving credit terms, along with common-stock reporting, senior debt references, risk-related governance and formal exhibits filed under the Exchange Act.
Boston Scientific Corporation (BSX): Stockholder Ellen M. Zane filed a Form 144 indicating a proposed sale of 2,901 common shares through Wells Fargo Clearing Services on the NYSE, with an aggregate market value of $296,591.81. The filing lists 1,481,751,634 shares outstanding and an approximate sale date of 10/28/2025.
The shares to be sold were acquired via a stock grant on 05/01/2025 in the amount of 2,901. The filing also notes sales during the past three months: on 10/27/2025, Zane sold 9,990 shares for $1,008,081.00 in gross proceeds.
Boston Scientific (BSX): Form 144 filed for a proposed insider sale. A selling securityholder noticed the sale of up to 9,990 shares of common stock through Wells Fargo Clearing Services, with an aggregate market value of $1,008,081. The approximate sale date is 10/27/2025 on the NYSE.
The shares were acquired via stock grants of 4,990 on 05/09/2020 and 5,000 on 05/07/2021. Shares outstanding were 1,481,751,634; this is a baseline figure, not the amount being sold. Proceeds would go to the selling holder, not the company.
Boston Scientific (BSX) reported that director John E. Sununu will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders. He has served on the Board since 2009, is a member of the Audit Committee, and chairs the Nominating and Governance Committee. He will continue in these roles until the 2026 Annual Meeting.
The Company stated that Mr. Sununu’s decision is not the result of any disagreement with the Company. The Board and its Nominating and Governance Committee will continue to review the Board’s size and composition and evaluate whether adding directors following his departure is in the Company’s best interest.
Boston Scientific Corporation furnished an update on its financials, announcing it issued a press release with results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The disclosure under Item 2.02 is being furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into Securities Act or Exchange Act filings. The company also listed Exhibit 104 for the cover page Inline XBRL tags.
Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), reported option activity and open-market sales on 10/01/2025. The filing shows a grant of a stock option to purchase 50,000 shares with an exercise price of $26.15; the option vests in four equal annual installments and the reported exercisable/expiration schedule lists an expiration of 12/01/2027. On the same date the reporting person sold 8,245 shares at a weighted average price of $98.9063 and 41,755 shares at a weighted average price of $98.3797, totaling 50,000 shares sold. The transactions were effected under a pre-established Rule 10b5-1 trading plan adopted 02/27/2025. The report disclaims beneficial ownership of 5,234 shares held by the reporting person’s child. The Form 4 was signed by an attorney-in-fact on 10/01/2025.
Insider sale notice for Boston Scientific (BSX): This Form 144 reports a proposed sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC on 10/01/2025 with an aggregate market value of $4,923,325 and 1,481,751,634 shares outstanding. The securities were acquired and are to be sold following a stock option exercise on 10/01/2025 with cash payment. The filer (identified in past sales as Joseph M. Fitzgerald) previously sold 50,000 shares on 09/02/2025 for $5,271,415 and 50,000 shares on 08/01/2025 for $5,231,665. The filer certifies no undisclosed material information and includes standard Rule 144 representations.
Boston Scientific Corporation announced that Jeffrey B. Mirviss, Executive Vice President and President, Peripheral Interventions, will retire effective December 1, 2025 and remain as a senior advisor through February 27, 2026. During the advisory period he will receive his current base salary of $705,000, prorated to the Retirement Date. The company expects to enter a Retirement Agreement providing payments and benefits materially consistent with its Executive Retirement Plan, 2025 Annual Bonus Plan and Long-Term Incentive Program and related equity awards.
Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), reported multiple transactions on 09/02/2025 effected under a pre-established Rule 10b5-1 trading plan adopted February 27, 2025. The report shows 50,000 shares acquired at a price of $26.15 (code M) and two dispositions totaling 50,000 shares sold in multiple trades at weighted average prices of $104.886 and $105.8486. After these transactions, the reporting person beneficially owned 178,342 shares directly, with an additional 5,234 shares held indirectly by his child which he disclaims beneficial ownership of. The filing includes an option related entry reflecting a 50,000-share option with the same $26.15 figure and references vesting in four equal annual installments beginning December 1, 2018.
The form is signed by an attorney-in-fact on behalf of the reporting person and discloses the reporting person will provide detailed per-price sale breakdowns upon request by the SEC or others.
Boston Scientific Corp. Form 144 notice reports a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $5,271,415.00, with an approximate sale date of 09/02/2025. The filing states these 50,000 shares were acquired the same day by stock option exercise and paid for in cash.
The filing also discloses prior sales by the same person, JOSEPH M FITZGERALD, totaling 156,372 shares across three transactions on 06/04/2025, 07/01/2025, and 08/01/2025, generating gross proceeds of $16,985,599.64 combined. The notice includes the seller's representation that no undisclosed material adverse information is known.